ST
HRTX icon

Spot Trading’s Heron Therapeutics HRTX Stock Holding History

Spot Trading’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,600
Closed -$39K – 3807
2015
Q3 		$39K Buy
1,600
+1,400
+700% +$46.7K ﹤0.01% 3335
2015
Q2 		$6K Buy
+200
New +$3.76K ﹤0.01% 3625

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spot Trading's HRTX Position: Q4 2015 in Review

Spot Trading sold out of Heron Therapeutics (HRTX) in Q4 2015, closing a stake of 143 shares — an estimated $3K sold.

Spot Trading first reported a position in HRTX in Q3 2015 and held it in 1 quarter. The position peaked at $3K in Q3 2015. 107 funds tracked by Wall St. Rank hold HRTX as of Q4 2015.

  • Spot Trading reported no remaining Heron Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Spot Trading sold 143 Heron Therapeutics shares in Q4 2015, an estimated $3K.
  • Spot Trading first reported a position in Heron Therapeutics in Q3 2015 and held it in 1 quarter.
  • Spot Trading's Heron Therapeutics position peaked at $3K in Q3 2015.
  • 107 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2015.

Based on Spot Trading's 13F filing for Q4 2015, filed 29 Jan 2016.